SAMANTHA GARRIS: Open Payments
NPI 1235884339 · RONDA, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$920 in 50 payments from 18 companies in 2025. Trend: 2023 $450 · 2024 $895 · 2025 $920
Food & beverage: $920
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $173 |
| AstraZeneca Pharmaceuticals LP | 5 | $145 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| Xeris Pharmaceuticals, Inc. | 2 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $61 |
| Amgen Inc. | 3 | $53 |
| ABBVIE INC. | 3 | $53 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Eisai Inc. | 2 | $30 |
| Exact Sciences Corporation | 2 | $30 |
Products named: REXULTI, AIRSUPRA, FARXIGA, CAPLYTA, KEVEYIS, OTEZLA, TRELEGY ELLIPTA, VRAYLAR.
Industry payments across NC — which companies pay providers there.
